

**Annual Report Published**

The 2019 Annual Report was published 13 May 2020.

[View here.](#)

**Q1 Interim Report to be published**

Dignitana's Q1 Interim Report will be published on 28 May 2020. [View here.](#)

**Dignitana Annual General Meeting**

Dignitana's AGM is scheduled for Thursday 25 June. The Notice to the Annual General Meeting will be posted by 28 May 2020.

**Loan received from COVID-19 US stimulus package**

Dignitana has obtained an unsecured loan in the amount of \$353,800 USD from the Payroll Protection Program (PPP), a small business loan program in the United States to help businesses recover from the impact of COVID-19. PPP funding is designated to offset payroll costs, rent, interest, and utilities. The loan may be partially or fully forgiven if the Company keeps employee counts and wages stable.

[Read more here.](#)

**Dignitana strengthens position with new loan**

Dignitana has obtained a new loan provided by Union Business Leasing (UBL) with an amount of \$1.5 million USD at market conditions. As [announced in August 2017](#), this facility can provide up to \$2.5 million USD in credit. Additionally, the Company has undertaken a number of initiatives to reduce overall operating costs to maintain maximum liquidity until the ongoing business environment becomes clearer. Facility partners continue to treat existing DigniCap patients and, with very few exceptions, are adding new patients as chemotherapy is essential and non-elective. New system deliveries have slowed however some sites are still accepting units and we are providing training online. To fully support customers remotely we have developed several digital resources. These will be further enhanced moving forward allowing the Company to perform new installations at a faster pace and more efficiently. As the pandemic evolves, we continue to work with our partners to find innovative ways for our mutual patients to access this vital therapy option with minimal disruption to critical workflows. [Read more here.](#)

**Master contract signed with Hartford HealthCare**

Dignitana has signed a master contract with [Hartford HealthCare](#) in the U.S. to provide DigniCap Delta at up to seven locations in Connecticut. [Read more here.](#)

**DigniCap Availability**

The DigniCap Scalp Cooling System is now available in 39 countries and in 30 states in the United States.

New locations since the last newsletter include:

- Northwell Health - Northern Westchester Hospital – Mount Kisco, New York
- Hartford HealthCare - St. Vincent's Medical Center – Bridgeport, Connecticut

**COVID-19 Updates**

Dignitana is monitoring the global developments of the pandemic. The health and safety of our patients, providers, employees and community are of critical importance. We are following recommendations from WHO, CDC and public health authorities to ensure we maintain the highest safety standards possible. The Company remains focused on providing DigniCap products and services to customers while recognizing that certain changes are necessary to conduct business in a responsible manner.

[Read Dignitana COVID-19 updates here.](#)

**Business update presented addressing COVID-19**

In April Dignitana CEO William Cronin presented a live webcast on the impact of COVID-19 and how Dignitana is moving forward in these uncertain times. The event was hosted by Redeye. [View webcast here.](#)

The April 2<sup>nd</sup> event included questions from investors with two excerpts reprinted below.

**Question:** *Can you comment on the launch of DigniCap Delta?*

**William Cronin:** *We are ahead of schedule and have placed as many Delta devices in 8 months as we shipped C3 devices in 3.5 years. That statistic alone tells the story of both the initial acceptance and success of the device in the marketplace.... The very aggressive rollout pace that we have maintained since the June clearance and August delivery of the first device has really helped us maintain our revenue stream during this time. However, we look forward to normal business conditions returning so that that very aggressive pace can continue or expand when possible.*

**Question:** *What can you tell us about reimbursement?*

**William Cronin:** *We have continued to see additional reimbursements at the patient level. We are working very aggressively with carriers... roughly 20% of our patients receive some level of reimbursement, complete or fractional, from their provider.... As usage proliferates, as more data becomes available, and as we continue to work with our patients to request coverage, we do anticipate a greater percentage of patients receiving coverage. So, we will work very aggressively to ensure that as many patients as possible are able to receive as much reimbursement for this as possible.*

Dignitana AB, Traktorgränden 3, SE-226 60 Lund Sweden

Per MAR guidelines, company announcements are posted at [www.dignitana.se](http://www.dignitana.se) and distributed to Nasdaq First North Growth Market, Nordic News Agencies, EU Transparency, and financial websites [Subscribe here](mailto:investorrelations@dignitana.com) to receive this newsletter by email or email [investorrelations@dignitana.com](mailto:investorrelations@dignitana.com)